Duchenne muscular dystrophy
Nature Reviews Disease Primers, vol. 7, pp. 13
Authors 5
-
Affiliation as printed
Department of Molecular Microbiology and Immunology and Department of Neurology, School of Medicine; Department of Biomedical Sciences, College of Veterinary Medicine; Department of Biomedical, Biological & Chemical Engineering, College of Engineering, University of Missouri, Columbia, MO, USA
Department of Biomedical Sciences, College of Veterinary Medicine
Department of Biomedical, Biological & Chemical Engineering, College of Engineering, University of Missouri, Columbia, MO, USA
Department of Molecular Microbiology and Immunology and Department of Neurology, School of Medicine
-
Universitair Ziekenhuis Leuven
Affiliation as printed
Department of Child Neurology, University Hospitals Leuven, Leuven, Belgium
-
National Center of Neurology and Psychiatry
Affiliation as printed
National Center of Neurology and Psychiatry, Tokyo, Japan
-
Università Cattolica del Sacro Cuore · Agostino Gemelli University Polyclinic · Centro Clinico Nemo
Affiliation as printed
Centro Clinico Nemo, Policlinico Gemelli, Rome, Italy
Peadiatric Neurology, Catholic University, Rome, Italy
-
Leiden University Medical Center
Affiliation as printed
Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands. a.m.aartsma-rus@lumc.nl
Department of Human Genetics, Leiden University Medical Center, Leiden, The Netherlands
Cited by 1,295 stored of 1,314
Cited by patents worldwide 15 (Lens.org)
-
TREATMENT FOR DISORDERS OF THE KIDNEY OR SPLEENWO2026087679A1 2026-04-30 Pending
-
TREATMENT FOR RENAL DISORDERSWO2026087678A1 2026-04-30 Pending
-
TREATMENT FOR METABOLIC DISORDERWO2026087695A1 2026-04-30 Pending
-
MICRODYSTROPHIN GENE THERAPY ADMINISTRATION FOR TREATMENT OF DYSTROPHINOPATHIESWO2026006341A1 2026-01-02 Pending
-
THERAPEUTIC OLIGONUCLEOTIDES FOR TREATING DISEASES BEING ASSOCIATED WITH OR CAUSED BY A MISSENSE, NONSENSE OR IN-FRAME INDEL MUTATIONWO2025262186A2 2025-12-26 Pending
-
ENDOXIFEN FOR TREATING DUCHENNE MUSCULAR DYSTROPHYWO2025207636A1 2025-10-02 Pending
-
TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERSEP4610278A2 2025-09-03 Pending
-
EXON 17-TARGETED NUCLEIC ACIDS, COMPOSITIONS, AND METHODS FOR TREATMENT OF DYSTROPHIN-BASED MYOPATHIESWO2025179121A1 2025-08-28 Pending
-
Dystrophin R16/R17 syntrophin PDZ fusion proteinsUS12337040B2 2025-06-24 Active
-
TARGETED SAPONIN-NUCLEIC ACID CONJUGATES FOR TREATMENT OF MUSCLE WASTING DISORDERSWO2023121446A1 2023-06-29 Patented
-
COMPOSITIONS COMPRISING THERAPEUTIC NUCLEIC ACID AND SAPONIN FOR THE TREATMENT OF MUSCLE-WASTING DISORDERSWO2023121445A1 2023-06-29 Pending
-
COMPOSITIONS COMPRISING THERAPEUTIC NUCLEIC ACID AND TARGETED SAPONIN FOR THE TREATMENT OF MUSCLE-WASTING DISORDERSWO2023121444A1 2023-06-29 Pending
-
TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY AND COMBINATIONS THEREOFWO2022241030A1 2022-11-17 Pending
-
MICRODYSTROPHIN GENE THERAPY ADMINISTRATION FOR TREATMENT OF DYSTROPHINOPATHIESWO2022232141A1 2022-11-03 Pending
-
DYSTROPHIN R16/R17 SYNTROPHIN PDZ FUSION PROTEINSUS20220175964A1 2022-06-09 Active